There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Bio-Rad Laboratories (BIO – Research Report) and Chimerix (CMRX – Research Report) with bullish sentiments.
Argenx Se (ARGX)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Argenx Se today and set a price target of $451.00. The company’s shares closed last Thursday at $380.01.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $479.00, implying a 24.2% upside from current levels. In a report issued on February 20, Wells Fargo also maintained a Buy rating on the stock with a $478.00 price target.
See the top stocks recommended by analysts >>
Bio-Rad Laboratories (BIO)
Citi analyst Patrick B Donnelly maintained a Buy rating on Bio-Rad Laboratories yesterday and set a price target of $400.00. The company’s shares closed last Thursday at $325.88.
According to TipRanks.com, Donnelly is a 4-star analyst with an average return of
Currently, the analyst consensus on Bio-Rad Laboratories is a Strong Buy with an average price target of $435.00, which is a 31.2% upside from current levels. In a report issued on February 15, RBC Capital also maintained a Buy rating on the stock with a $480.00 price target.
Chimerix (CMRX)
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Chimerix, with a price target of $11.00. The company’s shares closed last Thursday at $1.15.
According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Chimerix is a Strong Buy with an average price target of $7.75, which is a 520.0% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARGX:
- Argenx reports Q4 EPS ($1.68), consensus ($1.70)
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- ARGX Upcoming Earnings Report: What to Expect?
- argenx to Present at Upcoming Investor Conferences
- argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
